In the high-stakes world of clinical trials, there is a pervasive misconception among executives that "more sites" and "big-name institutions" are the silver bullets for meeting enrollment deadlines. The logic seems sound: partner with a subject matter expert at a world-renowned hospital to gain instant credibility and access to vast patient pools.